SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 342 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $473,945,956 | +7.4% | 3,909,800 | +1.4% | 0.10% | +13.1% |
| Q2 2023 | $441,486,282 | +9.2% | 3,855,102 | +31.4% | 0.08% | +5.0% |
| Q1 2023 | $404,339,742 | +22.2% | 2,933,612 | +14.9% | 0.08% | +21.2% |
| Q4 2022 | $330,955,614 | +17.0% | 2,554,064 | -0.2% | 0.07% | +10.0% |
| Q3 2022 | $282,856,000 | +36.3% | 2,558,869 | -7.6% | 0.06% | +42.9% |
| Q2 2022 | $207,553,000 | -0.9% | 2,768,861 | +3.3% | 0.04% | +16.7% |
| Q1 2022 | $209,399,000 | +15.9% | 2,680,478 | +33.6% | 0.04% | +24.1% |
| Q4 2021 | $180,708,000 | +39.6% | 2,006,753 | +43.4% | 0.03% | +31.8% |
| Q3 2021 | $129,421,000 | +10.5% | 1,399,462 | -7.1% | 0.02% | +15.8% |
| Q2 2021 | $117,129,000 | +3.6% | 1,506,672 | -0.7% | 0.02% | -5.0% |
| Q1 2021 | $113,113,000 | -49.3% | 1,517,674 | +16.0% | 0.02% | -51.2% |
| Q4 2020 | $223,054,000 | +23.9% | 1,308,312 | +2.1% | 0.04% | +10.8% |
| Q3 2020 | $180,021,000 | -0.7% | 1,281,937 | +13.3% | 0.04% | -7.5% |
| Q2 2020 | $181,376,000 | +96.1% | 1,131,194 | +19.7% | 0.04% | +66.7% |
| Q1 2020 | $92,481,000 | -24.6% | 945,412 | -0.6% | 0.02% | -7.7% |
| Q4 2019 | $122,733,000 | +32541.8% | 951,134 | +18987.6% | 0.03% | – |
| Q3 2019 | $376,000 | -64.1% | 4,983 | -27.7% | 0.00% | – |
| Q2 2019 | $1,048,000 | +42.2% | 6,894 | +11.6% | 0.00% | – |
| Q1 2019 | $737,000 | +9.8% | 6,177 | +0.5% | 0.00% | – |
| Q4 2018 | $671,000 | +10.2% | 6,147 | +63.1% | 0.00% | – |
| Q3 2018 | $609,000 | -20.3% | 3,770 | -34.7% | 0.00% | – |
| Q2 2018 | $764,000 | -35.5% | 5,775 | -63.9% | 0.00% | – |
| Q1 2018 | $1,184,000 | +42.5% | 15,981 | +18.2% | 0.00% | – |
| Q3 2016 | $831,000 | -27.0% | 13,526 | -71.5% | 0.00% | – |
| Q1 2014 | $1,139,000 | -52.3% | 47,400 | -59.6% | 0.00% | -100.0% |
| Q4 2013 | $2,388,000 | -84.9% | 117,253 | -65.1% | 0.00% | -80.0% |
| Q3 2013 | $15,857,000 | +5.2% | 335,743 | -15.2% | 0.01% | 0.0% |
| Q2 2013 | $15,069,000 | – | 396,028 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |